Type:1's Pack
Generic Name:Vinorelbine
Manufacturer:ZAS Corporation
Price:৳5750.00
Breast cancer, Ovarian cancer, Cervical cancer, Non-small cell lung cancer
IV Preparation May be diluted in syringe or bag Syringe: dilute to 1.5-3 mg/mL in NS or D5W IV Bag: dilute to 0.5-2 mg/mL in NS, 1/2NS, D5W, D5/½NS, LR or Ringer's IV Administration Administer IV over 6-10 min through sidearm of free-flowing IV closest to IV bag Then flush with 75-125 mL of one of the IV fluids
Oral Non-small cell lung cancer Adult: 60 mg/m2once wkly for 3 wk, may increase subsequently to 80 mg/m2 once wkly. If neutrophil count is < 500 cells/mm3 or between 500-1000 cells/mm3 on 2 separate occasions, keep dose at 60 mg/m2 for next 3 doses. Hepatic impairment: Massive liver metastases(>75% of liver volume replaced by the tumour): Decrease dose by 1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin >3 mg/100 ml: Reduce IV dose by 75%. Intravenous Non-small cell lung cancer Adult: As single agent: 30 mg/m2 wkly as infusion over 20-30 minutes (after diluting in 125 ml normal saline or glucose 5%) or as slow bolus over 5-10 minutes (after diluting in 20-50 ml normal saline or glucose 5%). Delay subsequent doses if neutrophil count is <2000 cells/mm3 until recovery. As combination therapy with cisplatin: 25-30 mg/m2 every 7 days. Hepatic impairment: Massive liver metastases(>75% of liver volume replaced by the tumour): Decrease dose by 1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin >3 mg/100 ml: Reduce IV dose by 75%. Cervical cancer Adult: 30 mg/m2/dose days 1 and 8 of a 21-day treatment cycle. Intravenous Breast cancer; Ovarian cancer Adult: 25 mg/m2/dose every 7 days. Hepatic impairment: Dose adjustments may be needed.
Hypersensitivity to vinorelbine or other vinca alkaloids; severe current or recent infection (within last 2 wk); neutropenia; thrombocytopenia; severe hepatic impairment. Intrathecal admin. Do not give concomitantly with radiotherapy if liver is in treatment field. Pregnancy, lactation.
Vinorelbine, a semisynthetic vinblastine derivative, binds to tubulin and inhibits microtubule formation. This disrupts the formation of the mitotic spindle thereby arresting the cell at metaphase.
Hepatic impairment. Compromised bone marrow reserve due to prior irradiation or chemotherapy; recovering marrow function from the effects of previous chemotherapy. Prior radiation therapy; past history or pre-existing neuropathy. CBC with differentials to be monitored prior to admin of subsequent doses. Delay subsequent doses, if neutrophil count < 2000 cells/mm3. Each admin to be followed by at least 250 ml of normal saline to flush the vein. Avoid extravasation. If extravasation occurs, stop infusion immediately, and flush the vein with normal saline solution; admin the remaining solution in another vein. Do not father a child during and up to six mth after treatment and females of childbearing potential to use effective method of contraception during treatment and three mth thereafter. When admin orally, capsules must be swallowed whole with water and not chewed or sucked. Lactation: not known if excreted in breast milk; do not nurse
>10% Leukopenia (92%),Granulocytopenia (90%),Anemia (83%),Elev AST (67%),Nausea (44%),Asthenia (36%),Constipation (35%),Fatigue (27%),Peripheral neuropathy (25%),Vomiting (20%),Anorexia (20%),Stomatitis (20%),Alopecia (12%) 1-10% Dyspnea (7%),Chest pain (5%),Rash (5%),SOB (3%),Hemorrhagic cystitis (1%),SIADH (1%)
Increased risk of granulocytopenia with cisplatin. Increased risk of neurotoxicity with paclitaxel, itraconazole, ketoconazole. Increased radiosensitising effects with prior or concomitant radiation therapy. Increased pulmonary toxicity with mitomycin. Increased myelotoxicity with zidovudine. Earlier onset and/or an increased severity of side effects with CYP3A inhibitors. Possible increase in vincristine levels with aprepitant. Possible infection with live vaccines.